Login to Your Account

Xoma seeks $50M at threshold of pivotal gevokizumab readouts

By Marie Powers
Staff Writer

Friday, December 13, 2013
Awaiting multiple gevokizumab (XOMA 052) data readouts in 2014, including the first Phase III data by midyear, on Friday Xoma Corp. priced a public offering of 9.5 million shares of common stock at $5.25 apiece, seeking to raise $50 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription